Why the study?
Cardiac arrhythmias carry high morbidity and mortality, requiring updated insights into the newest advancements in techniques, devices, and pharmacological therapies for management.
This review summarizes recent advancements in the management of atrial fibrillation and ventricular tachyarrhythmias, including device and pharmacological therapies.
Updates clinicians on AF/VT therapy advances; extends literature but leaves open need for prospective validation.
Cardiac arrhythmias are associated with several cardiac diseases and are prevalent in people with or without structural and valvular abnormalities. Ventricular arrhythmias (VA) can be life threating and their onset require immediate medical attention. Similarly, atrial fibrillation and flutter lead to stroke, heart failure and even death. Optimal treatment of VA is variable and depends on the medical condition associated with the rhythm disorder (which includes reversible causes such as myocardial ischemia or pro-arrhythmic drugs). While an implanted cardioverter defibrillator is often indicated in secondary prevention of VA. This review highlights the newest advancements in these techniques and management of ventricular and atrial tachyarrhythmias, along with pharmacological therapy.
No takes yet. Share an insight, caveat, or question.
Gheini et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: